Temporary GMP reprieve for Vietnam's drug producers
This article was originally published in Scrip
Pharmaceutical enterprises in Vietnam that do not yet have good manufacturing practice (GMP) certification to World Health Organizationstandards have been given more time to comply following appeals to the ministry of health.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.